Document Type
Article
Publication Date
2-10-2026
Journal / Book Title
Biologics: Targets and Therapy
Abstract
Background: The FDA’s October 2025 guidance proposes waiving Phase 3 comparative efficacy studies for biosimilars when analytical and pharmacokinetic similarity are demonstrated.
Methods: We conducted a net present value (NPV) analysis comparing traditional biosimilar development pathways (with Phase 3 comparative efficacy studies) to streamlined pathways utilizing FDA’s Phase 3 waiver framework. The model incorporates industry-benchmarked cost data (Phase 3 studies: $20–28M), development timelines (Phase 3 duration: 1–3 years). Economic outcomes were evaluated across three monoclonal antibody biosimilar programs representing high-, moderate-, and lower-complexity scenarios. Sensitivity analysis evaluated parameter variation across realistic ranges.
Results: Waiving Phase 3 studies reduces development costs by $25 million per program (18% reduction) and shortens timelines by 1.5 years (21% reduction). Risk-adjusted NPV improves by $25 million (29%), and minimum viable peak sales threshold decreases from $300 million to $250 million.
Conclusion: Phase 3 waivers can substantially reduce development costs (~$25M average), accelerate timelines (~1.5 years), and improve NPV (~25–29%) for well-characterized monoclonal antibody biosimilars meeting FDA’s analytical similarity and pharmacokinetic equivalence criteria. Economic benefits are conditional on robust analytical data, regulatory approval of waiver requests, and appropriate product selection (Tier 1/2/3 classification). Real-world realization requires post-implementation surveillance of FDA approval patterns, achieved cost reductions, and timeline compression beginning 2026–2027.
DOI
10.2147/BTT.S581013
Rights
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License.
MSU Digital Commons Citation
Ranbhor, Ranjit and Kulkarni, Priyanka, "Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development" (2026). Montclair State University Scholarship & Creative Works. 8.
https://digitalcommons.montclair.edu/allpubs/8
Published Citation
Ranbhor R, Kulkarni P. Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. Biologics. 2026;20:581013 https://doi.org/10.2147/BTT.S581013